Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 1811 to 1820 of 2581 total matches.
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
of Cornell University
EDITOR, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. ADVISORY BOARD: Jules Hirsch ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
In Brief: Effervescent Alendronate
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012 (Issue 1401)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1401)
October 15, 2012
Published ...
A new effervescent formulation of alendronate (Binosto – Mission) was recently approved by the FDA for treatment of osteoporosis. The new 70-mg effervescent tablet is considered bioequivalent to the usual 70-mg tablet formulations of alendronate (Fosamax, and generics), which are difficult to swallow and can cause esophageal injury.1 No published studies of the new formulation are available.LABELING — The new strawberry-flavored effervescent tablet should be dissolved over at least 5 minutes in 4 ounces of water (not mineral or flavored water) and stirred for 10 seconds before drinking. As...
Addendum: Dexlansoprazole for GERD
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
that our recent article on
Drugs for GERD and Peptic Ulcer Disease did not
include enough information ...
A reader commented that our recent article on
Drugs for GERD and Peptic Ulcer Disease did not
include enough information on dexlansoprazole
(Dexilant, and generics), a proton pump inhibitor
(PPI) claimed to provide "all-day and all-night relief
from heartburn". Dexlansoprazole recently became
available generically, but it is much more expensive
than other generic PPIs.
Salmeterol
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994 (Issue 921)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Rofecoxib for Osteoarthritis and Pain
The Medical Letter on Drugs and Therapeutics • Jul 02, 1999 (Issue 1056)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Ertapenem (Invanz) - A New Parenteral Carbapenem
The Medical Letter on Drugs and Therapeutics • Mar 18, 2002 (Issue 1126)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Ertapenem (er ta pen' em; Invanz - Merck), a carbapenem antibacterial with a narrower spectrum of activity than imipenem (Primaxin) or meropenem (Merrem), has been approved by the FDA for once-daily IV treatment of complicated intra-abdominal, urinary tract and skin and skin structure infections, acute pelvic infections, and community-acquired pneumonia.
New Treatments for Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002 (Issue 1133)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Several new treatments are now available for actinic keratoses (AKs), scaly pink papules commonly found on sun-exposed areas of the face, scalp, forearms and dorsal surface of the hands, particularly in the elderly. Some AKs regress spontaneously, but a few may progress to squamous cell carcinoma; the risk of progression has been estimated to be about 0.25% to 1% per year (EWB Jeffes III and EH Tang, Am J Clin Dermatol 2000; 1:167).
Sildenafil for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
as Viagra for treatment
of erectile dysfunction (Medical Letter 1998; 40:51).
DRUG THERAPY FOR PAH ...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
VariZIG for Prophylaxis After Exposure to Varicella
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
Letter
®
On Drugs and Therapeutics
Volume 48 (Issue 1241/1242)
August 14/28, 2006 ...
The US manufacturer of varicella zoster immune globulin (VZIG; Massachusetts Public Health Biologic Laboratories, Boston, MA) recently discontinued its production. A Canadian formulation, VariZIG (Varicella Zoster Immune Globulin [Human] - Cangene Corporation, Winnipeg) is now available in the US under an investigational new drug application expanded access protocol.
Insulin Glargine (Lantus) and Cancer Risk
The Medical Letter on Drugs and Therapeutics • Aug 24, 2009 (Issue 1319)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.